Semaglo-OB
Generic Name
Semaglutide
Manufacturer
Hypothetical Pharma Co.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| semaglo ob 24 mg injection | ৳ 1,500.00 | N/A |
Description
Overview of the medicine
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to diet and exercise. It is also used to improve glycemic control in adults with type 2 diabetes mellitus.
Uses & Indications
Dosage
Adults
Initial dose 0.25 mg subcutaneously once weekly, escalating gradually over 16-20 weeks to a maintenance dose of 2.4 mg once weekly. The 2.4 mg injection is the maintenance dose for weight management.
Elderly
No dose adjustment is required based on age. However, caution should be exercised due to potential for decreased renal function.
Renal_impairment
No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment. Not recommended for patients with End-Stage Renal Disease (ESRD) or those on dialysis.
How to Take
Administer subcutaneously once weekly, any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites. Do not inject intravenously or intramuscularly.
Mechanism of Action
Semaglutide acts as a GLP-1 receptor agonist, selectively binding to and activating the GLP-1 receptor. This leads to increased insulin secretion, decreased glucagon secretion, delayed gastric emptying, and reduced appetite, contributing to improved glycemic control and weight loss.
Pharmacokinetics
Onset
Initial effects on glucose and appetite can be seen within hours, but full therapeutic effects for weight loss develop over weeks.
Excretion
Primarily via urine (approximately 2/3) and feces (approximately 1/3) as metabolites and small amounts of intact semaglutide.
Half life
Approximately 1 week (about 7 days).
Absorption
Subcutaneous absorption leads to maximum concentration (Tmax) within 1-3 days.
Metabolism
Metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, similar to endogenous proteins.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any components of the product.
Drug Interactions
Oral Medications
Semaglutide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor patients receiving oral medications requiring rapid gastrointestinal absorption or with a narrow therapeutic index.
Insulin Secretagogues (e.g., sulfonylureas) or Insulin
Concomitant use with insulin secretagogues or insulin may increase the risk of hypoglycemia. A reduction in the dose of the insulin secretagogue or insulin may be necessary.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. If necessary, Semaglo-OB 2.4 mg injection can be stored at room temperature (below 30°C) for up to 28 days. Keep the pen cap on to protect from light. Discard the pen 28 days after first use.
Overdose
In case of overdose, monitor the patient for signs and symptoms of hypoglycemia and gastrointestinal adverse reactions. Supportive treatment should be initiated as dictated by the patient’s clinical signs and symptoms.
Pregnancy & Lactation
Data on semaglutide use in pregnant women are limited. Based on animal studies, there may be potential fetal harm. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether semaglutide is excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Semaglutide and any potential adverse effects on the breastfed infant.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any components of the product.
Drug Interactions
Oral Medications
Semaglutide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor patients receiving oral medications requiring rapid gastrointestinal absorption or with a narrow therapeutic index.
Insulin Secretagogues (e.g., sulfonylureas) or Insulin
Concomitant use with insulin secretagogues or insulin may increase the risk of hypoglycemia. A reduction in the dose of the insulin secretagogue or insulin may be necessary.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. If necessary, Semaglo-OB 2.4 mg injection can be stored at room temperature (below 30°C) for up to 28 days. Keep the pen cap on to protect from light. Discard the pen 28 days after first use.
Overdose
In case of overdose, monitor the patient for signs and symptoms of hypoglycemia and gastrointestinal adverse reactions. Supportive treatment should be initiated as dictated by the patient’s clinical signs and symptoms.
Pregnancy & Lactation
Data on semaglutide use in pregnant women are limited. Based on animal studies, there may be potential fetal harm. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether semaglutide is excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Semaglutide and any potential adverse effects on the breastfed infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 3 years when stored unopened in a refrigerator. Check specific product labeling.
Availability
Pharmacies, hospitals
Approval Status
FDA Approved (for chronic weight management and type 2 diabetes)
Patent Status
Under patent protection (for specific formulations/brands)
Clinical Trials
Extensive clinical trials (e.g., STEP program) have demonstrated the efficacy and safety of Semaglutide 2.4 mg for chronic weight management, showing significant weight loss compared to placebo.
Lab Monitoring
- Monitor for symptoms of pancreatitis (e.g., persistent severe abdominal pain).
- Monitor blood glucose levels regularly, especially if used with insulin or sulfonylureas, to adjust dosage and avoid hypoglycemia.
- Monitor renal function in patients with renal impairment.
Doctor Notes
- Emphasize the importance of diet and exercise as adjuncts to Semaglutide therapy for weight management.
- Counsel patients on proper injection technique and storage.
- Discuss potential gastrointestinal side effects and strategies for their management (e.g., smaller meals, adequate hydration).
Patient Guidelines
- Always use Semaglo-OB 2.4 mg injection exactly as prescribed by your doctor.
- Inject subcutaneously once a week. You can administer it any time of day, with or without food.
- Rotate your injection site each week (abdomen, thigh, or upper arm).
- Never share your pen with others, even if the needle has been changed, as this can transmit infections.
- Be aware of the symptoms of pancreatitis (severe stomach pain, vomiting) and thyroid tumors (lump in neck, difficulty swallowing) and seek medical attention if they occur.
Missed Dose Advice
If a dose is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If less than 2 days until the next scheduled dose, skip the missed dose and resume with the next scheduled dose. Do not double dose.
Driving Precautions
Semaglutide itself is unlikely to affect the ability to drive or use machines. However, if used in combination with other anti-diabetic medications that can cause hypoglycemia (e.g., insulin, sulfonylureas), patients should be warned about the risk of hypoglycemia and advised to take precautions.
Lifestyle Advice
- Combine Semaglo-OB 2.4 mg injection with a reduced-calorie diet and increased physical activity for optimal weight loss results.
- Maintain good hydration, especially during initial treatment, to manage potential gastrointestinal side effects.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Semaglo-OB Brand
Other medicines available under the same brand name
Semaglo-OB
Solution for injection (pre-filled pen)
Semaglo-OB
Subcutaneous Injection
Semaglo-OB
Solution for Injection (Pre-filled Pen)
Semaglo-OB
Injection (Subcutaneous)